Data Insights

Ivonescimab by Akeso for Gallbladder Cancer: Likelihood of Approval

Ivonescimab is under clinical development by Akeso and currently in Phase II for Gallbladder Cancer. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - Ivonescimab in Gallbladder Cancer

Data Insights

Ivonescimab by Akeso for Gastric Cancer: Likelihood of Approval

Ivonescimab is under clinical development by Akeso and currently in Phase II for Gastric Cancer. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - Ivonescimab in Gastric Cancer

Data Insights

Ivonescimab by Akeso for Cervical Cancer: Likelihood of Approval

Ivonescimab is under clinical development by Akeso and currently in Phase II for Cervical Cancer. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - Ivonescimab in Cervical Cancer

Data Insights

Ivonescimab by Akeso for Colorectal Cancer: Likelihood of Approval

Ivonescimab is under clinical development by Akeso and currently in Phase II for Colorectal Cancer. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - Ivonescimab in Colorectal Cancer

Data Insights

Cadonilimab by Akeso for Metastatic Castration-Resistant Prostate Cancer (mCRPC): Likelihood of Approval

Cadonilimab is under clinical development by Akeso and currently in Phase II for Metastatic Castration-Resistant Prostate Cancer (mCRPC). According to...

Likelihood of Approval and Phase Transition Success Rate Model - Cadonilimab in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Data Insights

Cadonilimab by Akeso for Squamous Non-Small Cell Lung Carcinoma: Likelihood of Approval

Cadonilimab is under clinical development by Akeso and currently in Phase II for Squamous Non-Small Cell Lung Carcinoma. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Cadonilimab in Squamous Non-Small Cell Lung Carcinoma

Data Insights

Cadonilimab by Akeso for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval

Cadonilimab is under clinical development by Akeso and currently in Phase II for Head And Neck Squamous Cell Carcinoma (HNSC)....

Likelihood of Approval and Phase Transition Success Rate Model - Cadonilimab in Head And Neck Squamous Cell Carcinoma (HNSC)

Data Insights

Cadonilimab by Akeso for Epithelial Ovarian Cancer: Likelihood of Approval

Cadonilimab is under clinical development by Akeso and currently in Phase II for Epithelial Ovarian Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Cadonilimab in Epithelial Ovarian Cancer

Data Insights

Cadonilimab by Akeso for Colorectal Cancer: Likelihood of Approval

Cadonilimab is under clinical development by Akeso and currently in Phase II for Colorectal Cancer. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - Cadonilimab in Colorectal Cancer

Data Insights

Ligufalimab by Akeso for Non-Hodgkin Lymphoma: Likelihood of Approval

Ligufalimab is under clinical development by Akeso and currently in Phase I for Non-Hodgkin Lymphoma. According to GlobalData, Phase I...

Likelihood of Approval and Phase Transition Success Rate Model - Ligufalimab in Non-Hodgkin Lymphoma

Data Insights

Ligufalimab by Akeso for Lymphoma: Likelihood of Approval

Ligufalimab is under clinical development by Akeso and currently in Phase I for Lymphoma. According to GlobalData, Phase I drugs...

Likelihood of Approval and Phase Transition Success Rate Model - Ligufalimab in Lymphoma

Data Insights

Ligufalimab by Akeso for Solid Tumor: Likelihood of Approval

Ligufalimab is under clinical development by Akeso and currently in Phase I for Solid Tumor. According to GlobalData, Phase I...

Likelihood of Approval and Phase Transition Success Rate Model - Ligufalimab in Solid Tumor

Data Insights

Cadonilimab by Akeso for Metastatic Pancreatic Cancer: Likelihood of Approval

Cadonilimab is under clinical development by Akeso and currently in Phase II for Metastatic Pancreatic Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Cadonilimab in Metastatic Pancreatic Cancer

Data Insights

Ivonescimab by Akeso for Ovarian Cancer: Likelihood of Approval

Ivonescimab is under clinical development by Akeso and currently in Phase II for Ovarian Cancer. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - Ivonescimab in Ovarian Cancer

Data Insights

Cadonilimab by Akeso for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval

Cadonilimab is under clinical development by Akeso and currently in Phase II for Pancreatic Ductal Adenocarcinoma. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Cadonilimab in Pancreatic Ductal Adenocarcinoma

Data Insights

Cadonilimab by Akeso for Gastric Cancer: Likelihood of Approval

Cadonilimab is under clinical development by Akeso and currently in Phase II for Gastric Cancer. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - Cadonilimab in Gastric Cancer

Data Insights

Cadonilimab by Akeso for Non-Small Cell Lung Cancer: Likelihood of Approval

Cadonilimab is under clinical development by Akeso and currently in Phase III for Non-Small Cell Lung Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Cadonilimab in Non-Small Cell Lung Cancer

Data Insights

Ivonescimab by Akeso for Small-Cell Lung Cancer: Likelihood of Approval

Ivonescimab is under clinical development by Akeso and currently in Phase II for Small-Cell Lung Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Ivonescimab in Small-Cell Lung Cancer

Data Insights

Cadonilimab by Akeso for Transitional Cell Cancer (Urothelial Cell Cancer): Likelihood of Approval

Cadonilimab is under clinical development by Akeso and currently in Phase II for Transitional Cell Cancer (Urothelial Cell Cancer). According...

Likelihood of Approval and Phase Transition Success Rate Model - Cadonilimab in Transitional Cell Cancer (Urothelial Cell Cancer)

Data Insights

Cadonilimab by Akeso for Small-Cell Lung Cancer: Likelihood of Approval

Cadonilimab is under clinical development by Akeso and currently in Phase II for Small-Cell Lung Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Cadonilimab in Small-Cell Lung Cancer